Boron Neutron Capture Therapy (BNCT) is neutron radiotherapy used to treat tumours cells previously doped with Boron-10. This therapy requires an epithermal beam for the treatment of deep and a thermal shallow ones. Thanks recent high-current commercial accelerators, Accelerator-Based Sources (ABNS) are competitive option providing therapeutic beams in hospitals. In this work, field generated b...

We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from ho...

Since 1998, we are performing clinical studies on treatment of GBM using conventional fractionated photon radiation therapy (CRT), proton beam therapy (PBT) or boron neutron capture therapy (BNCT). We investigated whether these radiation modalities improves the survival of patients with GBM. Sixty-eight cases of newly diagnosed GBM have been treated in our institution. After surgery, radiation ...

The aim of the present study was to evaluate the effect of bevacizumab on local tumor response and lung metastatic potential during boron neutron capture therapy (BNCT) and in particular, the response of intratumor quiescent (Q) cells. B16-BL6 melanoma tumor-bearing C57BL/6 mice were continuously administered bromodeoxyuridine (BrdU) to label all proliferating (P) tumor cells. The tumors were i...

background: boron neutron capture therapy (bnct) is a radiotherapy that combines biological targeting and high linear energy transfer. a potential therapeutic approach for non-small cell lung cancer (nsclc) is considered. however, dose in lung tumor is not homogeneous, and it will reduce the effect of bnct treatment. in order to improve the dose distribution of bnct, the multi-field irradiation...

Abstract Background We previously reported a phase II trial of accelerator-based boron neutron capture therapy (BNCT) for patients with malignant glioma, which showed long median overall survival 18.9 months. However, progression-free was 0.9 In this trial, bevacizumab permitted to use after progressive disease. The reason discrepance between short and speculated that progression disease includ...

Abstract Boron neutron capture therapy (BNCT) is a promising cancer treatment that selectively destroys tumor cells using beam. However, accurately and fast measuring the spatial distribution of flux critical to ensuring effective treatment. To address this challenge, Micromegas detectors are applied for first time measure beam in BNCT. Due high flux, large area, multiple components BNCT beam, ...